Target Enrollment Complete

ORCA-1

Nicotine E-Cigarette Cessation Trial

ORCA-V1 is a multi-center, double-blind, randomized, placebo-controlled, Phase 2 study being conducted in male or female adults who are daily nicotine e-cigarette users only, who intend to try to quit vaping and willing to set a quit date that is within 7-14 days from the start of cytisinicline treatment.

A total of approximately 150 subjects will be randomly assigned to one of two arms:

  • Arm A, 12 weeks cytisinicline + behavior support: N=100
  • Arm B, 12 weeks of placebo+ behavior support: N=50

Achieve Life Sciences Awarded Grant from the National Institutes of Health (NIH) for the Evaluation of Cytisinicline in Cessation of Nicotine E-cigarette Use

ORCA-V1 Trial Locations

ORCA-V1 is being conducted at the following locations in the US.

AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY DC

The General Hospital Coporation
d/b/a Massachusetts General Hospital
https://rally.partners.org/
617-726-7443

Alliance for Multispecialty Research
(Volunteer Research Group)
https://volresearch.com/
865-305-3784

Alliance for Multispecialty Research
(Central Kentucky Research)
https://www.amrlexington.com/
859-264-8999